RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th
RenovoRx, Inc. (RNXT)
Company Research
Source: GlobeNewswire
MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will participate in the Alliance Global Partners (AGP) Emerging AgBiotech/Bio-Solutions Virtual Showcase. The event will be hosted by Scott Henry, Managing Director and Healthcare Analyst, at AGP on November 20th, 2025. Mr. Bagai will share updates on RenovoRx’s continued commercial efforts and market traction, underscored by growing clinical demand and adoption of RenovoCath as a standalone, targeted drug-delivery device across both new and repeat customers. RenovoRx recently reported third quarter of 2025 financial results, demonstrating progress as year-to-date (end of September 30, 2025) revenue grew to approximately $900,000. He will discuss recent advance
Show less
Read more
Impact Snapshot
Event Time:
RNXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNXT alerts
High impacting RenovoRx, Inc. news events
Weekly update
A roundup of the hottest topics
RNXT
News
- RenovoRx Establishes RenovoCath® Medical Advisory BoardGlobeNewswire
- RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial OfficerGlobeNewswire
- RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific MeetingGlobeNewswire
- RenovoRx (NASDAQ:RNXT) was upgraded by analysts at Jones Trading to a "strong-buy" rating.MarketBeat
- RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific MeetingGlobeNewswire
RNXT
Earnings
- 5/15/25 - In-Line
RNXT
Sec Filings
- 2/6/26 - Form 8-K
- 1/30/26 - Form SCHEDULE
- 1/22/26 - Form 4
- RNXT's page on the SEC website